Atlas Trials

A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Clinical trial NCT06287918 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06287918
Sponsor
3H (Suzhou) Pharmaceuticals Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors With FGFR2 Alterations, Adult
Start date
2026-06-01
Primary completion
2028-03-01
Enrollment
130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.